Skip to content

Innoviva, Inc. INVA Free cash flow

Free cash flow at other companies

Pfizer logo
PfizerPFE
$2.18B+23.0%
Merck & Co. logo
Merck & Co.MRK
$2.93B+150%
AbbVie logo
AbbVieABBV
$3.56B+155%
Insmed logo
InsmedINSM
-$226.22M+16.9%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$48.46M+289%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.4B+9.7%
P/E3.5×
P/S4.1×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Calculated from Innoviva, Inc.’s reported figures.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s free cash flow?
Innoviva, Inc. (INVA) reported free cash flow of $34.79M in Q1 2026.
How has Innoviva, Inc.'s free cash flow changed year-over-year?
Innoviva, Inc.'s free cash flow decreased by 28.4% year-over-year, from $48.62M to $34.79M.
What is the long-term trend for Innoviva, Inc.'s free cash flow?
Over 3 years (2021 to 2024), Innoviva, Inc.'s free cash flow has grown at a -19.7% compound annual growth rate (CAGR), from $363.81M to $188.42M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.